Protara Therapeutics (TARA)
(Real Time Quote from BATS)
$2.31 USD
+0.02 (0.87%)
Updated Jul 26, 2024 02:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Income Statements
Fiscal Year end for Protara Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 44 | 67 | 47 | 34 | 15 |
Income After Depreciation & Amortization | -44 | -67 | -47 | -34 | -15 |
Non-Operating Income | 3 | 1 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -40 | -66 | -47 | -34 | -15 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -40 | -66 | -47 | -34 | -15 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -40 | -66 | -47 | -34 | -15 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -43 | -35 | -46 | -34 | -15 |
Depreciation & Amortization (Cash Flow) | 1 | 32 | 2 | 0 | 0 |
Income After Depreciation & Amortization | -44 | -67 | -47 | -34 | -15 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 11.33 | 11.26 | 11.23 | 7.23 | NA |
Diluted EPS Before Non-Recurring Items | -3.57 | -3.24 | -4.21 | -4.70 | NA |
Diluted Net EPS (GAAP) | -3.57 | -5.86 | -4.21 | -4.70 | -30.15 |
Fiscal Year end for Protara Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 11.85 | 11.04 | 10.70 | 12.14 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -11.85 | -11.04 | -10.70 | -12.14 |
Non-Operating Income | NA | 0.76 | 0.82 | 0.84 | 0.85 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -11.10 | -10.22 | -9.86 | -11.29 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -11.10 | -10.22 | -9.86 | -11.29 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -11.10 | -10.22 | -9.86 | -11.29 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 11.42 | 11.37 | 11.35 | 11.31 |
Diluted EPS Before Non-Recurring Items | NA | -0.97 | -0.90 | -0.87 | -1.00 |
Diluted Net EPS (GAAP) | NA | -0.97 | -0.90 | -0.87 | -1.00 |